YSC is the premier international organization dedicated to the critical issues unique to young women and breast cancer.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
Exavir Therapeutics is a preclinical stage biotechnology company focused on developing innovative therapies to eliminate HIV and other viral infections. The company specializes in ultra-long-acting nano-medicines that utilize proprietary nanoformulations to achieve sustained release of active pharmaceutical ingredients. This approach not only targets chronic viral infections but also addresses central nervous system disorders, aiming to provide patients with more convenient and effective treatment options. By adopting a broad modality-agnostic strategy, Exavir Therapeutics seeks to advance the field of antiviral therapeutics and improve patient outcomes.
Curebase is a software company that specializes in digital solutions for clinical trials, aiming to transform how medical providers manage these studies. Established in 2017 and based in San Francisco, California, the company offers a platform that streamlines various aspects of clinical trial execution, including participant eligibility, enrollment, education, and consent. By automating manual processes and facilitating trial distribution to clinics, Curebase significantly reduces recruitment times and overall costs associated with conducting clinical trials. Its services cater to medical device, biotech, and digital health startups, providing sponsors with essential data access to monitor trial progress effectively.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.
Destination Tomorrow is the Black-led Transgender & Gender Non-Conforming (TGNC) grant-making agency. The Destination Tomorrow offers services that take LGBTQ/TGNC individuals off the path of requiring emergency care with a focus on economic, social and mental empowerment on a holistic level.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
MYR GmbH is a biotechnology company based in Burgwedel, Germany, focused on developing therapeutics for chronic hepatitis B (HBV) and hepatitis delta virus (HDV) infections. Founded in 2010, the company’s lead product, Myrcludex B (bulevirtide), is a first-in-class entry inhibitor that prevents HBV from entering liver cells. This compound has advanced to a phase III clinical study for chronic HDV infection and has received Orphan Drug Designations from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Additionally, bulevirtide has been granted Breakthrough Therapy designation by the FDA and Promising Innovative Medicine designation by the British Medicines and Healthcare products Regulatory Agency (MHRA). Beyond its primary focus on hepatitis, MYR GmbH is exploring the drug's potential in treating various inflammatory and metabolic diseases, including dyslipidemia and nonalcoholic steatohepatitis (NASH), with ongoing clinical trials to support further development. The technology behind bulevirtide was initially developed at the University of Heidelberg and INSERM in France.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that focuses on developing monoclonal antibody-based therapies for cancer treatment. The company's lead product, sacituzumab govitecan, is an antibody-drug conjugate targeting metastatic triple-negative breast cancer, where it is positioned as a third-line treatment in the United States. Additionally, Immunomedics is advancing several other candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company also explores collaborative clinical efforts with major pharmaceutical partners to enhance the development and application of its products. Founded in 1982, Immunomedics aims to deliver innovative treatments to patients with serious diseases, leveraging its capabilities to drive scientific advancements and operational effectiveness. As of late 2020, it operates as a subsidiary of Gilead Sciences, Inc.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.
Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
The National AIDS Memorial relies solely on funding from longtime personal donors and corporate partners to support its mission as a dedicated space in the national landscape where millions of Americans touched directly or indirectly by AIDS can gather to heal, hope, and remember. The National AIDS Memorial, known as “the Grove”, was created more than twenty-eight years ago in San Francisco’s Golden Gate Park at the height of the HIV/AIDS epidemic as a place where those impacted by AIDS could both grieve and begin the process of healing. In 1996, legislation sponsored by U.S. Representative Nancy Pelosi was signed into law by President Clinton that elevated “the Grove” as this nation's sole federally-designated National AIDS Memorial. More than 50,000 individuals from around the world have contributed 225,000 volunteer hours to support the National AIDS Memorial and its mission.
Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.
Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.
Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.
Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability
Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for cancer treatment. It specializes in designing proprietary product candidates that aim to stimulate the patient's immune system to combat tumor cells effectively. By harnessing the body's natural defenses, Kite Pharma seeks to create novel strategies for managing various cancer types, ultimately aiming to improve outcomes for cancer patients. The company's commitment to advancing cell therapy positions it as a significant player in the biopharmaceutical landscape dedicated to addressing the challenges of cancer treatment.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
EpiTherapeutics is focused on developing innovative cancer therapies through the exploration of epigenetics, an area pioneered by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre in Copenhagen. The company specializes in small-molecule therapies that target enzymes crucial for regulating gene transcription, particularly histone demethylases. EpiTherapeutics has created a library of selective small molecule inhibitors aimed at modulating epigenetic regulation. Its lead pre-clinical compounds are currently being evaluated for their efficacy in treating various forms of cancer, positioning the company as a key player in advancing cancer treatment through epigenetic research.
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002, based in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, particularly focusing on nuclear receptors, and targets various disease areas, including liver diseases, gastrointestinal disorders, and cancer. Phenex is engaged in developing innovative therapeutics, such as RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. The company aims not only to create new treatments for established targets but also to explore novel molecular mechanisms, which can lead to the development of proprietary small molecules with transformative potential. Through its research, Phenex seeks to translate scientific findings into effective therapies that improve current treatment regimens for liver and cancer patients.
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
Pharmasset Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Its research centers on nucleoside analogs, which inhibit enzymes essential for viral replication. Pharmasset is advancing three product candidates: Clevudine, aimed at HBV, which is expected to enter Phase 3 clinical trials; R7128, a pro-drug for HCV currently in Phase 1 trials; and Racivir, an investigational treatment for HIV in Phase 2 trials. Through these efforts, Pharmasset seeks to provide effective treatment options for patients suffering from these viral infections.
Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.
Arresto Biosciences, Inc., a biotechnology company, develops medicines to treat cancer and fibrotic diseases by targeting molecules from the extracellular matrix. The company was incorporated in 2007 and is based in Palo Alto, California.
CGI Pharmaceuticals, founded in 2000 from Yale University, focuses on the discovery and development of small molecule therapeutics for oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The company employs a unique chemical-genetics method known as ASKA (Analog Sensitive Kinase Alleles) in collaboration with various biotech and pharmaceutical partners. CGI has established a comprehensive drug discovery infrastructure that includes proprietary kinase biology, chemistry, and drug metabolism expertise. This allows the company to maintain an extensive library of over 50,000 small molecule kinase inhibitors, all designed and synthesized internally. CGI has secured eight U.S. patents for its novel collection of kinase inhibitors, which serve as the foundation for its ongoing drug discovery and development programs, including those targeting specific kinases like Btk and Syk for various therapeutic applications.
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
Nycomed Limited, formerly known as Altana Pharma Limited. Nycomed Limited has been conducting manufacturing and tabletting operations at the Cork facility.
Raylo Chemicals Inc., a subsidiary of Germany-based specialty chemicals company.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. They believe that our advanced understanding of the biology of cardiovascular disease combined with their clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Triangle Pharmaceuticals
Acquisition in 2003
Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.